Avidea Biotech

Avidea Biotech is a biotechnology company specializing in the development of polymer-based immunotherapies and vaccines for cancer and infectious diseases. The company's core technology, the SNAP (Synthetic Neutralizing Antigen Particles) platform, allows for the precise assembly of antigens and adjuvants into nanoparticles that mimic the size and structure of viruses to optimize immune responses. By co-delivering these components, Avidea's candidates are designed to induce high-magnitude, antigen-specific T cell responses. In December 2021, Avidea was acquired by Vaccitech (now Barinthus Biotherapeutics) to integrate its nanoparticle delivery technology with Vaccitech's viral vector platforms. The company's lead programs include therapeutic vaccines for chronic Hepatitis B and HPV-related cancers.